Table 1 The demographic data and baseline characteristics of primary hepatic SCC/ASC patients and HCC patents

Patients

9

40

-

-

Gender

  Male

7(77.8%)

33(82.5%)

0.105

0.746

  Female

2(22.2%)

7(17.5%)

Age (years)

57.89 ± 11.062

54.55 ± 11.701

0.781

0.439

Cirrhosis

  Yes

4(44.4%)

21(52.5%)

0.005

0.946

  No

5(55.6%)

19(47.5%)

AFP

  ≤10 ng/ml

8(88.9%)

14(35%)

6.583

0.010

  >10 ng/ml

1(11.1%)

26(65%)

CA 19-9

  ≤37 U/ml

4(44.4%)

39(97.5%)

14.625

0.000

  >37 U/ml

5(55.6%)

1(2.5%)

Prothrombin time (second)

12.24 ± 1.098

12.11 ± 1.153

0.288

0.775

TBIL

  ≤2 mg/dl

8(88.9%)

27(67.5%)

0.766

0.382

  >2 mg/dl

1(11.1%)

13(32.5%)

ALT

  ≤40 U/l

6(66.7%)

17(42.5%)

0.889

0.346

  >40 U/l

3(33.3%)

23(57.5%)

AST

  ≤34 U/l

6(66.7%)

20(50%)

0.287

0.592

  >34 U/l

3(33.3%)

20(50%)

Extent of resection

  <Hemihep

7(77.8%)

35(87.5%)

0.051

0.821

  ≧Hemihep

2(22.2%)

5(12.5%)

Transfusion

  Yes

7(77.8%)

23(57.5%)

0.562

0.454

  No

2(22.2%)

17(42.5%)

Postoperative TACE

  Yes

3(33.3%)

24(60%)

1.171

0.279

  No

6(66.7%)

16(40%)

Tumor size (cm)

8.33 ± 3.082

10.33 ± 6.645

−0.873

0.387

TNM stage

  I

1(11.1%)

0

  II

3(33.3%)

7(17.5%)

  III

1(11.1%)

26(65%)

  IV

4(44.4%)

7(17.5%)